[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564653":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":47,"centralContacts":53,"locations":58,"responsibleParty":88,"collaborators":36,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":36,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":36,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":36,"overallStatus":60,"whyStopped":36,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Medical University of Lodz","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Rehabilitation","ACTIVE_COMPARATOR","Rehabilitation Treatment - a group of patients will be treated using a standardized rehabilitation protocol.",[13],"Other: Rehabilitation",{"label":15,"type":16,"description":17,"interventionNames":18},"Steroid","EXPERIMENTAL","Rehabilitation treatment combined with a subacromial corticosteroid injection. Patients will receive 1ml of methylprednisolone acetate (40mg\u002Fml) into the subacromial-subdeltoid bursa.",[19,13],"Drug: 1ml of Depo-Medrol® injection",{"label":21,"type":16,"description":22,"interventionNames":23},"PRP","Rehabilitation treatment combined with PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.",[13,24],"Drug: Tropocells® PRP injection",{"label":26,"type":16,"description":27,"interventionNames":28},"Nerve Block","Rehabilitation treatment combined with suprascapular nerve block. Patients will receive 4ml of 2% lidocaine around the suprascapular nerve.",[13,29],"Drug: Nerve block with 4ml of 2% lidocaine",[31,37,39,43],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","1ml of Depo-Medrol® injection","1ml of methylprednisolone acetate (40mg\u002Fml) injection into subacromial bursa.",[15],null,{"type":6,"name":9,"description":9,"armGroupLabels":38,"otherNames":36},[26,21,9,15],{"type":32,"name":40,"description":41,"armGroupLabels":42,"otherNames":36},"Nerve block with 4ml of 2% lidocaine","Nerve block with 4ml of 2% lidocaine around the suprascapular nerve",[26],{"type":32,"name":44,"description":45,"armGroupLabels":46,"otherNames":36},"Tropocells® PRP injection","Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.",[21],[48,51],{"name":49,"affiliation":5,"role":50},"Michał Kanak, MD","STUDY_CHAIR",{"name":52,"affiliation":5,"role":50},"Marcin Domżalski, Prof.",[54],{"name":49,"role":55,"phone":56,"phoneExt":36,"email":57},"CONTACT","178-334-0150","michal.kanak@umed.lodz.pl",[59],{"facility":5,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Lodz","Łódź Voivodeship","90-419","Poland","PL",{"type":67,"coordinates":68},"Point",[69,70],19.47395,51.77058,{"lat":70,"lon":69},[73,75,78,81,83,85,87],{"name":49,"role":55,"phone":74,"phoneExt":36,"email":57},"+48 783340150",{"name":76,"role":77,"phone":36,"phoneExt":36,"email":36},"Natalia Pawłuś, stud.","PRINCIPAL_INVESTIGATOR",{"name":79,"role":80,"phone":36,"phoneExt":36,"email":36},"Michał Kanak, MD.","SUB_INVESTIGATOR",{"name":82,"role":80,"phone":36,"phoneExt":36,"email":36},"Szymon Turkiewicz, stud.",{"name":84,"role":80,"phone":36,"phoneExt":36,"email":36},"Jędrzej Lesman, MD, PhD",{"name":86,"role":80,"phone":36,"phoneExt":36,"email":36},"Agata Gabryelska, MD, PhD",{"name":52,"role":80,"phone":36,"phoneExt":36,"email":36},{"type":89,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100564653","conservative-treatment-in-patients-with-supraspinatus-tendon-injury-100564653",false,"NCT06631976","Conservative Treatment in Patients With Supraspinatus Tendon Injury.","Comparison of Conservative Treatment Methods for Sleep Disorders, Pain, and Shoulder Function in Patients With Supraspinatus Tendon Injury.","Inclusion Criteria:\n\n1. Symptomatic partial incomplete thickness tear of the supraspinatus tendon, with a length below 1 cm and not exceeding 50% of the tendon thickness, confirmed by ultrasound examination.\n2. Sleep disturbance symptoms for at least 1 month due to shoulder pain - PSQI score \\> 5.\n3. Shoulder pain disrupting the quality of sleep.\n4. BMI \\\u003C 30.\n5. Age 40-75.\n\nExclusion Criteria:\n\n1. Other accompanying pain symptoms.\n2. History of shoulder surgery.\n3. Coexistence of psychiatric or neurological disorders.\n4. Presence of comorbidities that may disrupt sleep.\n5. Presence of risk factors impairing tissue regeneration and increasing the likelihood of injury progression - osteoporosis, diabetes, hypercholesterolemia.\n6. Alcohol dependence, nicotine addiction, passive smoking.\n7. Taking antibiotics from the fluoroquinolone group, sleep-affecting medications (such as melatonin, trazodone, zolpidem), antidepressants, antipsychotics, anxiolytics.\n8. Lack of patient consent, lack of cooperation, or impaired verbal-logical communication.","ALL","40 Years","75 Years",{"count":101,"type":102},40,"ESTIMATED","INTERVENTIONAL",[105],"NA","Rotator cuff injuries are a major cause of severe pain, often significantly impacting patients\\' sleep quality. For patients waiting for surgery or those not eligible for operative treatment, conservative treatment is recommended. In cases of minor injuries, physiotherapy is as effective as surgical intervention.\n\nThe aim of this study is: (1) to compare the speed, effectiveness, and durability of four implemented interventions in improving sleep quality, pain, and shoulder function, (2) to select the most optimal form of conservative treatment for patients with shoulder pain affecting sleep quality, and (3) to evaluate the expression of brain-derived neurotrophic factor (BDNF) and proBDNF (precursor) at the mRNA protein level before the planned intervention (T0), 1 month (T1), 3 months (T3), and 6 months (T6) after intervention.\n\nThe study results can assist physicians and physiotherapists in providing patients with therapy that not only relieves pain and improves function but also augments sleep quality, an aspect often overlooked in the literature yet greatly impacting patients\\' quality of life.",[108,109],"Supraspinatus Injury","Sleep Disturbance","2025-12-03",{"date":112,"type":113},"2025-12-10","ACTUAL",{"date":115,"type":113},"2024-06-04",{"date":117,"type":102},"2026-09",{"name":5,"class":6},1]